Non-liver mRNA Delivery
We describe efforts to reduce clearance by the liver, a key obstacle to the development of non-liver therapies. We then consider recent examples of nanoparticles that have delivered mRNA to non-liver tissues. Finally, we discuss current clinical mRNA programs, focusing on the COVID vaccines and highlighting lessons that may be applied to future mRNA drugs.PMID:34859663 | DOI:10.1021/acs.accounts.1c00601
Source: Cell Research - Category: Cytology Authors: David Loughrey James E Dahlman Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Chemistry | Coronavirus | COVID-19 | Cystic Fibrosis | Cytology | Emergency Medicine | Food and Drug Administration (FDA) | Heart | Infectious Diseases | Influenza | Influenza Vaccine | Lessons | Liver | Men | Muscular Dystrophy | Nanotechnology | Pfizer | Reflex Sympathetic Dystrophy | SARS | Sickle Cell Anemia | Urology & Nephrology | Vaccines